NextCell CEO invited speaker at the Swedish National ATMP Conference

NextCell Pharma AB ("NXTCL") announces that its CEO, Mathias Svahn PhD has been invited to speak at the 1st Swedish National Advanced Therapy Medicinal Product Conference held in Lund on March 15th.

The topic of the lecture will be ‘Mesenchymal Stem Cells in Clinical Trials for Treatment of Autoimmune Diseases’. More specifically it describes, how NXTCL leads the way with the development of its drug candidate, ProTrans, using pooled mesenchymal stem cells form the umbilical cord.

NXTCL is currently conducting a phase I/II trial using its drug candidate ProTrans for the treatment of adult patients newly diagnosed with type 1 diabetes.

Stay up to date with the latest development in NextCell Pharma



For more information about NextCell Pharma AB, please contact:

Mathias Svahn, CEO

Leo Groenewegen, CFO

Phone: 08-735 5595


About NextCell Pharma AB:

Stem cells are expected to change the way how many of today's life-threatening diseases are treated. NextCell

Pharma AB develops ProTrans™, a drug candidate consisting of stem cells for the primary treatment of autoimmuneand inflammatory diseases as well as for use in kidney transplants. ProTrans™ consists of selected stem cells derived from the umbilical cord tissue with NextCell Pharma AB's proprietary method. In addition, the company has a service called Cellaviva, Sweden's first and only IVO-approved stem cell bank for the family-saving of stem cells from umbilical cord blood and umbilical cord tissue.


Documents & Links